BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol. 2007;42:573-582. [PMID: 17653654 DOI: 10.1007/s00535-007-2060-x] [Cited by in Crossref: 177] [Cited by in F6Publishing: 170] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Dogru T, Genc H, Bagci S. C reactive protein levels in non-alcoholic fatty liver disease. J Hepatol 2012;56:507-8; author reply 508-10. [PMID: 21888877 DOI: 10.1016/j.jhep.2011.06.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Foroughi M, Maghsoudi Z, Khayyatzadeh S, Ghiasvand R, Askari G, Iraj B. Relationship between non-alcoholic fatty liver disease and inflammation in patients with non-alcoholic fatty liver. Adv Biomed Res 2016;5:28. [PMID: 27014655 DOI: 10.4103/2277-9175.176368] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
3 Chen JY, Chou CH, Tsai WC, Wang MC, Ho CS, Li YH, Tsai YS, Tsai LM. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens. 2012;6:253-260. [PMID: 22651911 DOI: 10.1016/j.jash.2012.04.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
4 Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies. Clin J Gastroenterol. 2015;8:1-9. [PMID: 25575848 DOI: 10.1007/s12328-014-0548-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
5 Song L, Qu D, Zhang Q, Jiang J, Zhou H, Jiang R, Li Y, Zhang Y, Yan H. Phytosterol esters attenuate hepatic steatosis in rats with non-alcoholic fatty liver disease rats fed a high-fat diet. Sci Rep. 2017;7:41604. [PMID: 28169366 DOI: 10.1038/srep41604] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 5.4] [Reference Citation Analysis]
6 El-Aziz RA, Alnaggar ARLR, Mohamed Nabih MI, Ali SM, Khattab H, El-Atty SA. Mac-2 binding protein in non-alcoholic fatty liver disease: Is it a reliable diagnostic biomarker? A pilot study. Clin Exp Hepatol 2020;6:28-34. [PMID: 32166121 DOI: 10.5114/ceh.2020.93053] [Reference Citation Analysis]
7 Tan C, Al-kalifah N, Lee W, Ser K, Lee Y, Chen J. HSCRP as surrogate marker in predicting long term effect of bariatric surgery on resolution of non-alcoholic steatohepatitis. Asian Journal of Surgery 2019;42:203-8. [DOI: 10.1016/j.asjsur.2018.04.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Alkhouri N, Eng K, Lopez R, Nobili V. Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD). Springerplus 2014;3:407. [PMID: 25126490 DOI: 10.1186/2193-1801-3-407] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
9 Sookoian S, Castaño GO, Burgueño AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-91. [PMID: 19896127 DOI: 10.1016/j.atherosclerosis.2009.10.011] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 5.9] [Reference Citation Analysis]
10 Tran A, Gual P. Non-alcoholic steatohepatitis in morbidly obese patients. Clin Res Hepatol Gastroenterol. 2013;37:17-29. [PMID: 23347840 DOI: 10.1016/j.clinre.2012.07.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
11 Price JC, Wang R, Seaberg EC, Budoff MJ, Kingsley LA, Palella FJ, Witt MD, Post WS, Thio CL. The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus. Open Forum Infect Dis 2017;4:ofx153. [PMID: 28929125 DOI: 10.1093/ofid/ofx153] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
12 Tarantino G, Conca P, Riccio A, Tarantino M, Di Minno MN, Chianese D, Pasanisi F, Contaldo F, Scopacasa F, Capone D. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J Transl Med. 2008;6:72. [PMID: 19038040 DOI: 10.1186/1479-5876-6-72] [Cited by in Crossref: 47] [Cited by in F6Publishing: 58] [Article Influence: 3.4] [Reference Citation Analysis]
13 Uddin MG, Hossain MS, Rahman MA, Uddin AHMM, Bhuiyan MS. Elemental Zinc Is Inversely Associated with C-Reactive Protein and Oxidative Stress in Chronic Liver Disease. Biol Trace Elem Res 2017;178:189-93. [DOI: 10.1007/s12011-016-0919-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
14 Tarantino G, Colicchio P, Conca P, Finelli C, Di Minno MN, Tarantino M, Capone D, Pasanisi F. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J Inflamm (Lond). 2009;6:6. [PMID: 19291292 DOI: 10.1186/1476-9255-6-6] [Cited by in Crossref: 43] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
15 Davidson MD, Kukla DA, Khetani SR. Microengineered cultures containing human hepatic stellate cells and hepatocytes for drug development. Integr Biol (Camb) 2017;9:662-77. [PMID: 28702667 DOI: 10.1039/c7ib00027h] [Cited by in Crossref: 33] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
16 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 22.0] [Reference Citation Analysis]
17 Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol Res 2013;43:508-15. [PMID: 23067270 DOI: 10.1111/j.1872-034X.2012.01106.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
18 Chen W, Wang JB, Abnet CC, Dawsey SM, Fan JH, Yin LY, Yin J, Taylor PR, Qiao YL, Freedman ND. Association between C-reactive protein, incident liver cancer, and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2015;24:386-92. [PMID: 25613115 DOI: 10.1158/1055-9965.EPI-14-1038] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 13.3] [Reference Citation Analysis]
20 Zhu QX, Deng CS. Detection of TNF-α, TGF-β1 and hs-CRP and its clinical significance in non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2008; 16(34): 3910-3912 [DOI: 10.11569/wcjd.v16.i34.3910] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Tan CH, Al-Kalifah N, Ser KH, Lee YC, Chen JC, Lee WJ. Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. Surg Obes Relat Dis 2018;14:1600-6. [PMID: 30077664 DOI: 10.1016/j.soard.2018.05.024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
22 Ono M. Is rosuvastatin effective for non-alcoholic steatohepatitis with dyslipidemia? Hepatol Res 2012;42:1055-7. [PMID: 23094853 DOI: 10.1111/j.1872-034X.2012.01052.x] [Reference Citation Analysis]
23 Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Inamori M, Kobayashi N, Kubota K, Saito S, Maeyama S, Hotta K, Nakajima A. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci. 2010;55:808-814. [PMID: 19267193 DOI: 10.1007/s10620-009-0771-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
24 Villela-Nogueira CA, Leite NC, Cardoso CR, Salles GF. NAFLD and Increased Aortic Stiffness: Parallel or Common Physiopathological Mechanisms? Int J Mol Sci 2016;17:E460. [PMID: 27104526 DOI: 10.3390/ijms17040460] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
25 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
26 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
27 Simon TG, Corey KE, Chung RT, Giugliano R. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Dig Dis Sci 2016;61:3425-35. [DOI: 10.1007/s10620-016-4330-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
28 Fan Z, Li N, Xu Z, Wu J, Fan X, Xu Y. An interaction between MKL1, BRG1, and C/EBPβ mediates palmitate induced CRP transcription in hepatocytes. Biochim Biophys Acta Gene Regul Mech 2019;1862:194412. [PMID: 31356989 DOI: 10.1016/j.bbagrm.2019.194412] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
29 Belalcazar LM, Papandonatos GD, Erar B, Peter I, Alkofide H, Balasubramanyam A, Brautbar A, Kahn SE, Knowler WC, Ballantyne CM, McCaffery JM, Huggins GS; Genetics Subgroup of the Look AHEAD Study*. Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition: Glucokinase Regulatory Protein-Leu446Pro Variant in Look AHEAD. Circ Cardiovasc Genet 2016;9:71-8. [PMID: 26578543 DOI: 10.1161/CIRCGENETICS.115.001192] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
30 Pisto P, Ukkola O, Santaniemi M, Kesäniemi YA. Plasma adiponectin--an independent indicator of liver fat accumulation. Metabolism 2011;60:1515-20. [PMID: 21565369 DOI: 10.1016/j.metabol.2011.03.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
31 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
32 Heeringa M, Hastings A, Yamazaki S, de Koning P. Serum biomarkers in nonalcoholic steatohepatitis: value for assessing drug effects? Biomark Med. 2012;6:743-757. [PMID: 23227839 DOI: 10.2217/bmm.12.87] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
33 Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord 2022;22:49. [PMID: 35216556 DOI: 10.1186/s12902-022-00967-y] [Reference Citation Analysis]
34 Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306-17. [PMID: 19065650 DOI: 10.1002/hep.22603] [Cited by in Crossref: 372] [Cited by in F6Publishing: 347] [Article Influence: 28.6] [Reference Citation Analysis]
35 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
36 Baskar S, Jhaveri S, Alkhouri N. Cardiovascular risk in pediatric nonalcoholic fatty liver disease: recent advances. Clinical Lipidology 2015;10:351-62. [DOI: 10.2217/clp.15.26] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Yoneda M, Fujita K, Nozaki Y, Endo H, Takahashi H, Hosono K, Suzuki K, Mawatari H, Kirikoshi H, Inamori M, Saito S, Iwasaki T, Terauchi Y, Kubota K, Maeyama S, Nakajima A. Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study: Efficacy of ezetimibe for NASH. Hepatology Research 2010;40:566-73. [DOI: 10.1111/j.1872-034x.2010.00644.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
38 Fujita T. Who is benefited by one daily glass of wine? Hepatology 2008;48:1022-3; author reply 1023-4. [PMID: 18756480 DOI: 10.1002/hep.22466] [Reference Citation Analysis]
39 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
40 Jeon D, Son M, Shim J. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status. Nutrients 2021;13:1720. [PMID: 34069568 DOI: 10.3390/nu13051720] [Reference Citation Analysis]
41 Tam CS, Viardot A, Clément K, Tordjman J, Tonks K, Greenfield JR, Campbell LV, Samocha-Bonet D, Heilbronn LK. Short-term overfeeding may induce peripheral insulin resistance without altering subcutaneous adipose tissue macrophages in humans. Diabetes 2010;59:2164-70. [PMID: 20547978 DOI: 10.2337/db10-0162] [Cited by in Crossref: 71] [Cited by in F6Publishing: 70] [Article Influence: 5.9] [Reference Citation Analysis]
42 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
43 Constantinescu C, SĂndulescu L, SĂftoiu A. The Role of Elastography in Non-Alcoholic Fatty Liver Disease. Curr Health Sci J 2020;46:255-69. [PMID: 33304627 DOI: 10.12865/CHSJ.46.03.07] [Reference Citation Analysis]
44 Banerjee A, Mukherjee S, Maji BK. Worldwide flavor enhancer monosodium glutamate combined with high lipid diet provokes metabolic alterations and systemic anomalies: An overview. Toxicol Rep 2021;8:938-61. [PMID: 34026558 DOI: 10.1016/j.toxrep.2021.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ohishi W, Cologne JB, Fujiwara S, Suzuki G, Hayashi T, Niwa Y, Akahoshi M, Ueda K, Tsuge M, Chayama K. Serum interleukin-6 associated with hepatocellular carcinoma risk: a nested case-control study. Int J Cancer. 2014;134:154-163. [PMID: 23784949 DOI: 10.1002/ijc.28337] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.7] [Reference Citation Analysis]
46 Sundaresan S, Vijayagopal P, Mills N, Imrhan V, Prasad C. A mouse model for nonalcoholic steatohepatitis. The Journal of Nutritional Biochemistry 2011;22:979-84. [DOI: 10.1016/j.jnutbio.2010.08.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
47 Shah RA, Kowdley KV. Obeticholic acid for the treatment of nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2020;14:311-321. [PMID: 32241197 DOI: 10.1080/17474124.2020.1748498] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
48 Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Ishii A, Iijima H, Nishiguchi S. Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis. Hepatol Res 2016;46:575-83. [PMID: 26418076 DOI: 10.1111/hepr.12595] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
49 Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, Mohan V. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther 2012;14:152-8. [PMID: 22149546 DOI: 10.1089/dia.2011.0213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
50 Arslan U, Kocaoğlu I, Balcı M, Duyuler S, Korkmaz A. The association between impaired collateral circulation and non-alcoholic fatty liver in patients with severe coronary artery disease. J Cardiol 2012;60:210-4. [PMID: 22738690 DOI: 10.1016/j.jjcc.2012.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
51 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
52 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010;16:4784-4791. [PMID: 20939106 DOI: 10.3748/wjg.v16i38.4784] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Fricker ZP, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Benjamin EJ, Long MT. Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study. Clin Gastroenterol Hepatol 2019; 17: 1157-1164. e4. [PMID: 30476583 DOI: 10.1016/j.cgh.2018.11.037] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
54 Williams KH, Sullivan DR, Nicholson GC, George J, Jenkins AJ, Januszewski AS, Gebski VJ, Manning P, Tan YM, Donoghoe MW, Ehnholm C, Young S, O'Brien R, Buizen L, Twigg SM, Keech AC. Opposite associations between alanine aminotransferase and γ-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism 2016;65:783-93. [PMID: 27085785 DOI: 10.1016/j.metabol.2015.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
55 Duval C, Thissen U, Keshtkar S, Accart B, Stienstra R, Boekschoten MV, Roskams T, Kersten S, Müller M. Adipose tissue dysfunction signals progression of hepatic steatosis towards nonalcoholic steatohepatitis in C57BL/6 mice. Diabetes. 2010;59:3181-3191. [PMID: 20858684 DOI: 10.2337/db10-0224] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 10.3] [Reference Citation Analysis]
56 Targher G, Bertolini L, Rodella S, Lippi G, Franchini M, Zoppini G, Muggeo M, Day CP. NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. Obesity (Silver Spring). 2008;16:1394-1399. [PMID: 18369343 DOI: 10.1038/oby.2008.64] [Cited by in Crossref: 127] [Cited by in F6Publishing: 133] [Article Influence: 9.1] [Reference Citation Analysis]
57 Haufe S, Engeli S, Budziarek P, Utz W, Schulz-Menger J, Hermsdorf M, Wiesner S, Otto C, Haas V, de Greiff A, Luft FC, Boschmann M, Jordan J. Cardiorespiratory fitness and insulin sensitivity in overweight or obese subjects may be linked through intrahepatic lipid content. Diabetes 2010;59:1640-7. [PMID: 20357364 DOI: 10.2337/db09-1200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
58 Paul J. Recent advances in non-invasive diagnosis and medical management of non-alcoholic fatty liver disease in adult. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00043-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
59 Kuroda R, Nogawa K, Watanabe Y, Morimoto H, Sakata K, Suwazono Y. Association between High-Sensitive C-Reactive Protein and the Development of Liver Damage in Japanese Male Workers. Int J Environ Res Public Health 2021;18:2985. [PMID: 33799436 DOI: 10.3390/ijerph18062985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 You T, Arsenis NC, Disanzo BL, Lamonte MJ. Effects of exercise training on chronic inflammation in obesity : current evidence and potential mechanisms. Sports Med 2013;43:243-56. [PMID: 23494259 DOI: 10.1007/s40279-013-0023-3] [Cited by in Crossref: 126] [Cited by in F6Publishing: 118] [Article Influence: 14.0] [Reference Citation Analysis]
61 Misra VL, Khashab M, Chalasani N. Nonalcoholic fatty liver disease and cardiovascular risk. Curr Gastroenterol Rep. 2009;11:50-55. [PMID: 19166659 DOI: 10.1007/s11894-009-0008-4] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 5.1] [Reference Citation Analysis]
62 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
63 Cai J, Zhang XJ, Ji YX, Zhang P, She ZG, Li H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 2020;126:679-704. [PMID: 32105577 DOI: 10.1161/CIRCRESAHA.119.316337] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
64 Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, Kaul I, Sowa J, Canbay A, Töx U, Steffen HM. NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One 2013;8:e58360. [PMID: 23555578 DOI: 10.1371/journal.pone.0058360] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
65 Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116:539-564. [PMID: 19243311 DOI: 10.1042/cs20080253] [Cited by in Crossref: 160] [Cited by in F6Publishing: 74] [Article Influence: 12.3] [Reference Citation Analysis]
66 Vallée D, Blanc M, Lebeaupin C, Bailly-Maitre B. [Endoplasmic reticulum stress response and pathogenesis of non-alcoholic steatohepatitis]. Med Sci (Paris) 2020;36:119-29. [PMID: 32129747 DOI: 10.1051/medsci/2020008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
67 Pariente A. [Diagnosis and management of non alcoholic fatty liver disease]. Gastroenterol Clin Biol 2009;33:413-24. [PMID: 19375255 DOI: 10.1016/j.gcb.2009.02.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
68 Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: Pathophysiological mechanisms and implications. J Hepatol. 2016;65:425-443. [PMID: 27091791 DOI: 10.1016/j.jhep.2016.04.005] [Cited by in Crossref: 190] [Cited by in F6Publishing: 185] [Article Influence: 31.7] [Reference Citation Analysis]
69 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
70 Terán Lantarón A, Crespo García J. [Non-alcoholic fatty liver disease. How and who to screen]. Gastroenterol Hepatol 2011;34:278-88. [PMID: 21429628 DOI: 10.1016/j.gastrohep.2010.11.010] [Reference Citation Analysis]
71 Yoon SB, Lee IS, Choi MH, Lee K, Ham H, Oh HJ, Park SH, Lim CH, Choi MG. Impact of Fatty Liver on Acute Pancreatitis Severity. Gastroenterol Res Pract 2017;2017:4532320. [PMID: 28536603 DOI: 10.1155/2017/4532320] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
72 Bisaccia G, Ricci F, Mantini C, Tana C, Romani GL, Schiavone C, Gallina S. Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med 2020;8:2050312120933804. [PMID: 32612827 DOI: 10.1177/2050312120933804] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Targher G, Bertolini L, Chonchol M, Rodella S, Zoppini G, Lippi G, Zenari L, Bonora E. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia. 2010;53:1341-1348. [PMID: 20369224 DOI: 10.1007/s00125-010-1720-1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 7.8] [Reference Citation Analysis]
74 Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M. Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease. Front Immunol 2022;13:880298. [DOI: 10.3389/fimmu.2022.880298] [Reference Citation Analysis]
75 Kammoun HL, Hainault I, Ferré P, Foufelle F. Nutritional related liver disease: targeting the endoplasmic reticulum stress: . Current Opinion in Clinical Nutrition and Metabolic Care 2009;12:575-82. [DOI: 10.1097/mco.0b013e32833189db] [Cited by in Crossref: 28] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
76 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
77 Paquissi FC. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Front Immunol 2016;7:490. [PMID: 27891128 DOI: 10.3389/fimmu.2016.00490] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
78 Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? Journal of Hepatology 2011;54:1020-9. [DOI: 10.1016/j.jhep.2010.11.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 9.2] [Reference Citation Analysis]
79 Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29:939-60. [DOI: 10.1210/er.2008-0009] [Cited by in Crossref: 338] [Cited by in F6Publishing: 318] [Article Influence: 24.1] [Reference Citation Analysis]
80 Hossain IA, Akter S, Bhuiyan FR, Shah MR, Rahman MK, Ali L. Subclinical inflammation in relation to insulin resistance in prediabetic subjects with nonalcoholic fatty liver disease. BMC Res Notes. 2016;9:266. [PMID: 27169860 DOI: 10.1186/s13104-016-2071-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
81 Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol 2020;20:40-54. [DOI: 10.1038/s41577-019-0198-4] [Cited by in Crossref: 179] [Cited by in F6Publishing: 171] [Article Influence: 59.7] [Reference Citation Analysis]
82 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
83 Skat-rørdam J, Pedersen K, Skovsted GF, Gregersen I, Vangsgaard S, Ipsen DH, Latta M, Lykkesfeldt J, Tveden-nyborg P. Vitamin C Deficiency May Delay Diet-Induced NASH Regression in the Guinea Pig. Antioxidants 2022;11:69. [DOI: 10.3390/antiox11010069] [Reference Citation Analysis]
84 Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol. 2011;55:660-665. [PMID: 21238518 DOI: 10.1016/j.jhep.2010.12.017] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 5.0] [Reference Citation Analysis]
85 Botella-Carretero JI, Balsa JA, Vázquez C, Peromingo R, Díaz-Enriquez M, Escobar-Morreale HF. Retinol and alpha-tocopherol in morbid obesity and nonalcoholic fatty liver disease. Obes Surg 2010;20:69-76. [PMID: 18830789 DOI: 10.1007/s11695-008-9686-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
86 Tilg H, Moschen AR. Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov 2014;9:687-96. [PMID: 24766298 DOI: 10.1517/17460441.2014.911283] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
87 Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis. 2015;239:192-202. [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001] [Cited by in Crossref: 175] [Cited by in F6Publishing: 164] [Article Influence: 25.0] [Reference Citation Analysis]
88 Marzuillo P, Grandone A, Perrone L, Miraglia del Giudice E. Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21(21): 6444-6450 [PMID: 26074683 DOI: 10.3748/wjg.v21.i21.6444] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
89 Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med 2008;14:222-31. [PMID: 18235842 DOI: 10.2119/2007-00119.Tilg] [Cited by in Crossref: 431] [Cited by in F6Publishing: 211] [Article Influence: 30.8] [Reference Citation Analysis]
90 Utzschneider KM, Largajolli A, Bertoldo A, Marcovina S, Nelson JE, Yeh MM, Kowdley KV, Kahn SE. Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women. J Diabetes Complications 2014;28:177-84. [PMID: 24360972 DOI: 10.1016/j.jdiacomp.2013.11.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
91 Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, Nishimura T, Yoh K, Aizawa N, Sakai Y, Ikeda N, Takashima T, Iijima H, Nishiguchi S. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. Hepatol Res 2016;46:613-21. [PMID: 26406984 DOI: 10.1111/hepr.12596] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
92 Kaneko H, Anzai T, Nagai T, Anzai A, Takahashi T, Mano Y, Morimoto K, Maekawa Y, Itoh H, Yoshikawa T, Ogawa S, Fukuda K. Human C-reactive protein exacerbates metabolic disorders in association with adipose tissue remodelling. Cardiovascular Research 2011;91:546-55. [DOI: 10.1093/cvr/cvr088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
93 Verhaegh P, Bavalia R, Winkens B, Masclee A, Jonkers D, Koek G. Noninvasive Tests Do Not Accurately Differentiate Nonalcoholic Steatohepatitis From Simple Steatosis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2018;16:837-61. [DOI: 10.1016/j.cgh.2017.08.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
94 Fairfield CJ, Drake TM, Pius R, Bretherick AD, Campbell A, Clark DW, Fallowfield JA, Hayward C, Henderson NC, Joshi PK, Mills NL, Porteous DJ, Ramachandran P, Semple RK, Shaw CA, Sudlow CLM, Timmers PRHJ, Wilson JF, Wigmore SJ, Harrison EM, Spiliopoulou A. Genome-Wide Association Study of NAFLD Using Electronic Health Records. Hepatol Commun 2021. [PMID: 34535985 DOI: 10.1002/hep4.1805] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Imajo K, Yoneda M, Fujita K, Kessoku T, Tomeno W, Ogawa Y, Shinohara Y, Sekino Y, Mawatari H, Nozaki Y, Kirikoshi H, Taguri M, Toshima G, Takahashi J, Saito S, Wada K, Nakajima A. Oral choline tolerance test as a novel noninvasive method for predicting nonalcoholic steatohepatitis. J Gastroenterol 2014;49:295-304. [PMID: 23503837 DOI: 10.1007/s00535-013-0776-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
96 Bottazzi B, Inforzato A, Messa M, Barbagallo M, Magrini E, Garlanda C, Mantovani A. The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling. J Hepatol. 2016;64:1416-1427. [PMID: 26921689 DOI: 10.1016/j.jhep.2016.02.029] [Cited by in Crossref: 82] [Cited by in F6Publishing: 85] [Article Influence: 13.7] [Reference Citation Analysis]
97 Pacana T, Fuchs M. The cardiovascular link to nonalcoholic fatty liver disease: a critical analysis. Clin Liver Dis. 2012;16:599-613. [PMID: 22824483 DOI: 10.1016/j.cld.2012.05.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
98 Takeuchi M, Takino JI, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi SI. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol 2014; 6(12): 880-893 [PMID: 25544875 DOI: 10.4254/wjh.v6.i12.880] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
99 Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595-599. [PMID: 18662837 DOI: 10.1016/j.jhep.2008.05.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
100 Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48:662-669. [PMID: 18666246 DOI: 10.1002/hep.22402] [Cited by in Crossref: 84] [Cited by in F6Publishing: 74] [Article Influence: 6.0] [Reference Citation Analysis]
101 Suzuki K, Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Nozaki Y, Takahashi H, Abe Y, Inamori M, Shimamura T. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatol Res. 2010;40:693-700. [PMID: 20412325 DOI: 10.1111/j.1872-034x.2010.00643.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
102 Akazawa Y, Nakashima R, Matsuda K, Okamaoto K, Hirano R, Kawasaki H, Miuma S, Miyaaki H, Malhi H, Abiru S, Itoh M, Kondo H, Fukuoka J, Nakao K, Nakashima M. Detection of DNA damage response in nonalcoholic fatty liver disease via p53-binding protein 1 nuclear expression. Mod Pathol 2019;32:997-1007. [PMID: 30809000 DOI: 10.1038/s41379-019-0218-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Koga M, Murai J, Saito H, Mukai M, Kasayama S. Serum glycated albumin levels, but not glycated hemoglobin, is low in relation to glycemia in non-diabetic men with nonalcoholic fatty liver disease with high alanine aminotransferase levels. Clinical Biochemistry 2010;43:1023-5. [DOI: 10.1016/j.clinbiochem.2010.05.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
104 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
105 Uehara D, Hayashi Y, Seki Y, Kakizaki S, Horiguchi N, Tojima H, Yamazaki Y, Sato K, Yasuda K, Yamada M, Uraoka T, Kasama K. Non-invasive prediction of non-alcoholic steatohepatitis in Japanese patients with morbid obesity by artificial intelligence using rule extraction technology. World J Hepatol 2018; 10(12): 934-943 [PMID: 30631398 DOI: 10.4254/wjh.v10.i12.934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
106 . Current world literature. Curr Opin Rheumatol 2008;20:729-35. [PMID: 18946335 DOI: 10.1097/BOR.0b013e328317a234] [Reference Citation Analysis]
107 Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi S. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol. 2014;6:880-893. [PMID: 25544875 DOI: 10.4254/wjh.6.i12.880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
108 Valle-Martos R, Valle M, Martos R, Cañete R, Jiménez-Reina L, Cañete MD. Liver Enzymes Correlate With Metabolic Syndrome, Inflammation, and Endothelial Dysfunction in Prepubertal Children With Obesity. Front Pediatr 2021;9:629346. [PMID: 33665176 DOI: 10.3389/fped.2021.629346] [Reference Citation Analysis]
109 Amacher DE. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers 2014;19:541-52. [PMID: 25189636 DOI: 10.3109/1354750X.2014.958535] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
110 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
111 Rabelo F, Oliveira CPMS, Faintuch J, Mazo DFC, Lima VMR, Stefano JT, Barbeiro HV, Soriano FG, Alves VAF, Carrilho FJ. Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. OBES SURG 2010;20:906-12. [DOI: 10.1007/s11695-010-0181-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
112 Chiang C, Huang C, Chan W, Chen J, Leu H. The severity of non-alcoholic fatty liver disease correlates with high sensitivity C-reactive protein value and is independently associated with increased cardiovascular risk in healthy population. Clinical Biochemistry 2010;43:1399-404. [DOI: 10.1016/j.clinbiochem.2010.09.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
113 Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698. [PMID: 18471547 DOI: 10.1053/j.gastro.2008.02.077] [Cited by in Crossref: 233] [Cited by in F6Publishing: 228] [Article Influence: 16.6] [Reference Citation Analysis]
114 Armstrong LE, Guo GL. Role of FXR in Liver Inflammation during Nonalcoholic Steatohepatitis. Curr Pharmacol Rep 2017;3:92-100. [PMID: 28983452 DOI: 10.1007/s40495-017-0085-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
115 Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, Batur Y. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2009;9:16. [PMID: 19222849 DOI: 10.1186/1471-230x-9-16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
116 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol 2010;5:2166-71. [PMID: 20724519 DOI: 10.2215/CJN.05050610] [Cited by in Crossref: 128] [Cited by in F6Publishing: 53] [Article Influence: 10.7] [Reference Citation Analysis]
118 Wei H, Qu H, Wang H, Deng H. Associations between sitting time and non-alcoholic fatty liver diseases in Chinese male workers: a cross-sectional study. BMJ Open 2016;6:e011939. [PMID: 27609847 DOI: 10.1136/bmjopen-2016-011939] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
119 Hong SH, Lee JS, Kim JA, Lee YB, Roh E, Hee Yu J, Kim NH, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi KM. Glycemic variability and the risk of nonalcoholic fatty liver disease : A nationwide population-based cohort study. Diabetes Res Clin Pract 2021;177:108922. [PMID: 34146602 DOI: 10.1016/j.diabres.2021.108922] [Reference Citation Analysis]
120 Bilgir O, Bilgir F, Bozkaya G, Calan M. Changes in the levels of endothelium-derived coagulation parameters in nonalcoholic fatty liver disease. Blood Coagulation & Fibrinolysis 2014;25:151-5. [DOI: 10.1097/mbc.0000000000000009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
121 Bell LN, Lee L, Saxena R, Bemis KG, Wang M, Theodorakis JL, Vuppalanchi R, Alloosh M, Sturek M, Chalasani N. Serum proteomic analysis of diet-induced steatohepatitis and metabolic syndrome in the Ossabaw miniature swine. Am J Physiol Gastrointest Liver Physiol 2010;298:G746-54. [PMID: 20167877 DOI: 10.1152/ajpgi.00485.2009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
122 Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008;8:53. [PMID: 19014569 DOI: 10.1186/1471-230X-8-53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
123 Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. Non-alcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS One. 2013;8:e49286. [PMID: 23326306 DOI: 10.1371/journal.pone.0049286] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
124 Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin resistance. Mol Med. 2008;14:222-231. [PMID: 18235842 DOI: 10.2119/2007-00119] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
125 Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(30): 3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
126 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 25.3] [Reference Citation Analysis]
127 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 95] [Article Influence: 13.8] [Reference Citation Analysis]
128 Erreni M, Manfredi AA, Garlanda C, Mantovani A, Rovere-Querini P. The long pentraxin PTX3: A prototypical sensor of tissue injury and a regulator of homeostasis. Immunol Rev 2017;280:112-25. [PMID: 29027216 DOI: 10.1111/imr.12570] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
129 Shih KL, Su WW, Chang CC, Kor CT, Chou CT, Chen TY, Wu HM. Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:24031. [PMID: 27079922 DOI: 10.1038/srep24031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
130 Fujii Y, Nouso K, Matsushita H, Kariyama K, Sakurai T, Takahashi Y, Chiba H, Hui S, Ito Y, Ohta M, Okada H. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis. The Journal of Applied Laboratory Medicine 2020;5:1206-15. [DOI: 10.1093/jalm/jfaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Mencarelli A, Cipriani S, Renga B, Bruno A, D'Amore C, Distrutti E, Fiorucci S. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS One. 2012;7:e45425. [PMID: 23029000 DOI: 10.1371/journal.pone.0045425] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 6.2] [Reference Citation Analysis]
132 Oda E, Watanabe K. High-sensitivity C-reactive protein and metabolic syndrome (insulin resistance syndrome), including nonalcoholic steatohepatitis. J Gastroenterol. 2008;43:312-313; author reply 313. [PMID: 18458848 DOI: 10.1007/s00535-008-2175-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
133 Dunn W, Schwimmer JB. Reply:. Hepatology 2008;48:1023-4. [DOI: 10.1002/hep.22502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
134 Wallert M, Börmel L, Lorkowski S. Inflammatory Diseases and Vitamin E-What Do We Know and Where Do We Go? Mol Nutr Food Res 2021;65:e2000097. [PMID: 32692879 DOI: 10.1002/mnfr.202000097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
135 Baranova A, Tran TP, Birerdinc A, Younossi ZM. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2011;33:801-814. [PMID: 21251033 DOI: 10.1111/j.1365-2036.2011.04579.x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 65] [Article Influence: 7.0] [Reference Citation Analysis]
136 Vajro P, Lenta S, Socha P, Dhawan A, Mckiernan P, Baumann U, Durmaz O, Lacaille F, Mclin V, Nobili V. Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents: Position Paper of the ESPGHAN Hepatology Committee. Journal of Pediatric Gastroenterology & Nutrition 2012;54:700-13. [DOI: 10.1097/mpg.0b013e318252a13f] [Cited by in Crossref: 273] [Cited by in F6Publishing: 119] [Article Influence: 27.3] [Reference Citation Analysis]
137 Treeprasertsuk S, Lopez-Jimenez F, Lindor KD. Nonalcoholic fatty liver disease and the coronary artery disease. Dig Dis Sci 2011;56:35-45. [PMID: 20464495 DOI: 10.1007/s10620-010-1241-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
138 Tanaka M, Okada H, Hashimoto Y, Kumagai M, Nishimura H, Oda Y, Fukui M. Relationship between nonalcoholic fatty liver disease and muscle quality as well as quantity evaluated by computed tomography. Liver Int 2019;40:120-30. [DOI: 10.1111/liv.14253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
139 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
140 Fierbinteanu-Braticevici C, Dina I, Petrisor A, Tribus L, Negreanu L, Carstoiu C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol 2010; 16(38): 4784-4791 [PMID: 20939106 DOI: 10.3748/wjg.v16.i38.4784] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
141 Lim HS, Choi J, Lee B, Kim SG, Kim YS, Yoo JJ. Association between Inflammatory Biomarkers and Nutritional Status in Fatty Liver. Clin Nutr Res 2020;9:182-94. [PMID: 32789148 DOI: 10.7762/cnr.2020.9.3.182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Alkhouri N, Carter-Kent C, Elias M, Feldstein AE. Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease. Clin Lipidol. 2011;6:305-314. [PMID: 22162978 DOI: 10.2217/clp.11.19] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
143 Zhao J, Liu J, Pang X, Zhang X, Wang S, Wu D. Rosiglitazone attenuates angiotensin II-induced C-reactive protein expression in hepatocytes via inhibiting AT1/ROS/MAPK signal pathway. International Immunopharmacology 2016;31:178-85. [DOI: 10.1016/j.intimp.2015.12.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
144 Guzel FB, Ozturk I, Gisi K, Ispiroglu M, Akkus G, Erken E, Altunoren O, Gungor O. The relationship between hepatic fibrosis and arterial stiffness in hemodialysis patients. Semin Dial 2021. [PMID: 34390271 DOI: 10.1111/sdi.13011] [Reference Citation Analysis]
145 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
146 Rocha R, Cotrim HP, Bitencourt AG, Barbosa DB, Santos AS, Almeida Ade M, Cunha B, Guimarães I. Nonalcoholic fatty liver disease in asymptomatic Brazilian adolescents. World J Gastroenterol 2009;15:473-7. [PMID: 19152453 DOI: 10.3748/wjg.15.473] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
147 Parikh NS, Jesudian A, Kamel H, Hanley DF, Ziai WC, Murthy SB; VISTA-ICH Collaboration. Liver Fibrosis and Perihematomal Edema Growth in Primary Intracerebral Hemorrhage. Neurocrit Care 2021;34:983-9. [PMID: 32808155 DOI: 10.1007/s12028-020-01081-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
148 Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, Luben R, Bingham S, Khaw KT, Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia 2009;52:1040-7. [PMID: 19326095 DOI: 10.1007/s00125-009-1338-3] [Cited by in Crossref: 125] [Cited by in F6Publishing: 128] [Article Influence: 9.6] [Reference Citation Analysis]
149 Demir M, Lang S, Nierhoff D, Drebber U, Hardt A, Wedemeyer I, Schulte S, Quasdorff M, Goeser T, Töx U, Steffen H. Stepwise Combination of Simple Noninvasive Fibrosis Scoring Systems Increases Diagnostic Accuracy in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2013;47:719-26. [DOI: 10.1097/mcg.0b013e3182819a89] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
150 Porter SA, Pedley A, Massaro JM, Vasan RS, Hoffmann U, Fox CS. Aminotransferase levels are associated with cardiometabolic risk above and beyond visceral fat and insulin resistance: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2013;33:139-46. [PMID: 23162012 DOI: 10.1161/ATVBAHA.112.300075] [Cited by in Crossref: 34] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
151 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008;28:503-22. [DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
152 Cyr B, Keane RW, de Rivero Vaccari JP. ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study. Int J Mol Sci 2020;21:E8580. [PMID: 33203036 DOI: 10.3390/ijms21228580] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
153 Takino J, Kobayashi Y, Takeuchi M. The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity. J Gastroenterol 2010;45:646-55. [DOI: 10.1007/s00535-009-0193-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
154 Jung SJ, Hwang JH, Park SH, Choi EK, Ha KC, Baek HI, Shin DG, Seo JH, Chae SW. A 12-week, randomized, double-blind study to evaluate the efficacy and safety of liver function after using fermented ginseng powder (GBCK25). Food Nutr Res 2020;64. [PMID: 32425736 DOI: 10.29219/fnr.v64.3517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
155 Banerjee A, Das D, Paul R, Roy S, Das U, Saha S, Dey S, Adhikary A, Mukherjee S, Maji BK. Mechanistic study of attenuation of monosodium glutamate mixed high lipid diet induced systemic damage in rats by Coccinia grandis. Sci Rep 2020;10:15443. [PMID: 32963259 DOI: 10.1038/s41598-020-72076-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
156 Li N, Zhang GW, Zhang JR, Jin D, Li Y, Liu T, Wang RT. Non-alcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis. 2015;25:218-223. [PMID: 25456154 DOI: 10.1016/j.numecd.2014.10.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
157 Hagymási K, Lengyel G. Non-alcoholic steatosis/steatohepatitis – 2010. Orvosi Hetilap 2010;151:1940-5. [DOI: 10.1556/oh.2010.28989] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
158 Gambino R, Musso G, Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal. 2011;15:1325-1365. [PMID: 20969475 DOI: 10.1089/ars.2009.3058] [Cited by in Crossref: 97] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
159 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
160 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
161 Jamali R. Non-Alcoholic Fatty Liver Disease: Diagnosis and Evaluation of Disease Severity. Thrita J Med Sci 2013;2:43-51. [DOI: 10.5812/thrita.11795] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
162 Ajmal MR, Yaccha M, Malik MA, Rabbani MU, Ahmad I, Isalm N, Abdali N. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. Indian Heart J 2014;66:574-9. [PMID: 25634387 DOI: 10.1016/j.ihj.2014.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
163 Romain C, Gaillet S, Carillon J, Vidé J, Ramos J, Izard J, Cristol J, Rouanet J. Vineatrol and Cardiovascular Disease: Beneficial Effects of a Vine-Shoot Phenolic Extract in a Hamster Atherosclerosis Model. J Agric Food Chem 2012;60:11029-36. [DOI: 10.1021/jf303549t] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
164 Pettersson-Pablo P, Samyn D, Wasim J, Vink M. Reference interval for type III procollagen (PIIINP) using the Advia centaur PIIINP assay in adults and elderly. Scand J Clin Lab Invest 2021;81:649-52. [PMID: 34779323 DOI: 10.1080/00365513.2021.2001045] [Reference Citation Analysis]
165 Zhu C, Huang D, Ma H, Qian C, You H, Bu L, Qu S. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol 2022;13:848937. [DOI: 10.3389/fendo.2022.848937] [Reference Citation Analysis]
166 Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51:1947-1953. [PMID: 18762907 DOI: 10.1007/s00125-008-1135-4] [Cited by in Crossref: 256] [Cited by in F6Publishing: 243] [Article Influence: 18.3] [Reference Citation Analysis]
167 Ahn AL, Choi JK, Kim MN, Kim SA, Oh EJ, Kweon HJ, Cho DY. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med. 2013;34:199-205. [PMID: 23730487 DOI: 10.4082/kjfm.2013.34.3.199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
168 Rehman K, Akash MS. Mechanisms of inflammatory responses and development of insulin resistance: how are they interlinked? J Biomed Sci 2016;23:87. [PMID: 27912756 DOI: 10.1186/s12929-016-0303-y] [Cited by in Crossref: 150] [Cited by in F6Publishing: 140] [Article Influence: 25.0] [Reference Citation Analysis]
169 Baldry EL, Aithal GP, Kaye P, Idris IR, Bennett A, Leeder PC, Macdonald IA. Effects of short-term energy restriction on liver lipid content and inflammatory status in severely obese adults: Results of a randomized controlled trial using 2 dietary approaches. Diabetes Obes Metab 2017;19:1179-83. [PMID: 28230324 DOI: 10.1111/dom.12918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
170 Ndumele CE, Nasir K, Conceiçao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31:1927-1932. [PMID: 21546603 DOI: 10.1161/atvbaha.111.228262] [Cited by in Crossref: 99] [Cited by in F6Publishing: 58] [Article Influence: 9.0] [Reference Citation Analysis]
171 Bieghs V, Rensen PC, Hofker MH, Shiri-sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 2012;220:287-93. [DOI: 10.1016/j.atherosclerosis.2011.08.041] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
172 Lebeaupin C, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol 2018;69:927-47. [PMID: 29940269 DOI: 10.1016/j.jhep.2018.06.008] [Cited by in Crossref: 198] [Cited by in F6Publishing: 195] [Article Influence: 49.5] [Reference Citation Analysis]
173 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379. [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005] [Cited by in Crossref: 288] [Cited by in F6Publishing: 280] [Article Influence: 20.6] [Reference Citation Analysis]
174 Johnson ND, Wu X, Still CD, Chu X, Petrick AT, Gerhard GS, Conneely KN, DiStefano JK. Differential DNA methylation and changing cell-type proportions as fibrotic stage progresses in NAFLD. Clin Epigenetics 2021;13:152. [PMID: 34353365 DOI: 10.1186/s13148-021-01129-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Zhang WW, He X, Lv XP, Li Y, Li HT, Luo R, Li CP, He M. Screening of differentially expressed serum proteins in patients with HBV-related liver fibrosis by iTRAQ combined with mass spectrometry. Shijie Huaren Xiaohua Zazhi 2012; 20(29): 2789-2794 [DOI: 10.11569/wcjd.v20.i29.2789] [Reference Citation Analysis]
176 Lim JW, Dillon J, Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World J Gastroenterol 2014; 20(26): 8325-8340 [PMID: 25024592 DOI: 10.3748/wjg.v20.i26.8325] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
177 Jamialahmadi T, Nematy M, Bo S, Ponzo V, Jangjoo A, Goshayeshi L, Tasbandi A, Nikiforov NG, Sahebkar A. Associations between Pre-Bariatric High-Sensitivity C-Reactive Protein and Post-Surgery Outcomes. Diagnostics (Basel) 2021;11:721. [PMID: 33919641 DOI: 10.3390/diagnostics11040721] [Reference Citation Analysis]
178 Chao Y, Wu P, Huang J, Chiu Y, Lee J, Chen S, Chang J, Hwang S, Chen H. Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts. Biomedicines 2022;10:892. [DOI: 10.3390/biomedicines10040892] [Reference Citation Analysis]
179 Hirahatake KM, Bruno RS, Bolling BW, Blesso C, Alexander LM, Adams SH. Dairy Foods and Dairy Fats: New Perspectives on Pathways Implicated in Cardiometabolic Health. Adv Nutr 2020;11:266-79. [PMID: 31555799 DOI: 10.1093/advances/nmz105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]